Portola Pharma (PTLA) Tops Q4 EPS by 17c

Portola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($0.95), $0.17 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $13.69 million versus the consensus estimate of $3.98 million.

2017 Annual Financial GuidanceFor the fiscal year 2017, Portola expects total GAAP operating expenses to be between $323 million and $344 million. For the fiscal year 2017, Portola expects total pro-forma operating expenses to be between $290 million and $310 million, excluding stock-based compensation. These expenses will be primarily for manufacturing of both andexanet and betrixaban, support of ongoing clinical trials and preparation for the potential commercial launches of betrixaban and AndexXa.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• S&P 500 may pull back before midterms, but Citi says buy the dip
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue